Krystal Biotech, Inc. (KRYS)
Nasdaq · Healthcare · Biotechnology
$334.85+3.90%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $9.9B
- P/E (trailing)
- 42.0
- Forward P/E
- 35.9
- 52-week range
- $179.19 – $382.54
- 52-week change
- +76.09%
- EPS (trailing)
- $7.98
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $389M (+33.95%)
- Net income
- $205M
- Operating margin
- 41.4%
- Diluted EPS
- $6.84
- Free cash flow
- $189M
From the company’s annual report on SEC EDGAR.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Headquarters: Pittsburgh, United States · 295 employees · krystalbio.com